ScreenerHero
SLVSelvita S.A.
GPW · PL · Healthcare · Diagnostics & Research · selvita.com
28.80PLN+0.52%Mkt Cap: 133.16M $P/E: —

Selvita S.A. provides drug discovery, drug development, and contract testing services in Poland. The company offers computer-aided drug design and artificial intelligence solutions, including structure-based drug design,…

Industry Peers

Diagnostics & Research
Screen all
TMO
Thermo Fisher Scientific Inc.
$226.85BUSDP/E 33.1
DHR
Danaher Corporation
$151.78BUSDP/E 38.6
LONN
Lonza Group Ltd
$46.70BUSDP/E 37.9
NTRA
Natera, Inc.
$46.86BUSD
IDXX
IDEXX Laboratories, Inc.
$44.35BUSDP/E 39.5
A
Agilent Technologies, Inc.
$44.14BUSDP/E 31.4
IQV
IQVIA Holdings Inc
$41.03BUSDP/E 31.0
WAT
Waters Corporation
$40.83BUSDP/E 105.8
ILMN
Illumina, Inc.
$30.95BUSDP/E 38.2
MTD
Mettler-Toledo International, Inc.
$28.55BUSDP/E 32.1
LH
Labcorp Holdings Inc.
$26.80BUSDP/E 27.4
DGX
Quest Diagnostics Incorporated
$26.68BUSDP/E 25.6
GH
Guardant Health, Inc.
$21.92BUSD
MEDP
Medpace Holdings, Inc.
$16.98BUSDP/E 35.8
ERF
Eurofins Scientific SE
$13.64BUSDP/E 25.3
CRL
Charles River Laboratories International, Inc.
$13.84BUSD
RVTY
Revvity Inc. Common Stock
$13.33BUSDP/E 57.4
BIM
bioMerieux S.A.
$9.51BUSDP/E 19.0
QIA
Qiagen N.V.
$8.69BUSDP/E 22.8
TWST
Twist Bioscience Corp.
$8.93BUSD

Key Statistics

Company
Market Cap133.16M $
Enterprise Value170.68M $
Revenue (TTM)91.01M $
Gross Profit74.30M $
Net Income (TTM)205.90K $
Revenue/Share4.958 USD
Last Price28.80 PLN
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees899
CountryPL
SectorHealthcare
IndustryDiagnostics & Research
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)28.70
PEG—
EV/EBITDA16.22
EV/Revenue1.88
P/S1.46
P/B1.66
EPS (TTM)-0.21
EPS (Forward)—
52W Range
24.4517% of range49.40
52W High49.40 PLN
52W Low24.45 PLN
Profitability
Gross Margin80.55%
Oper. Margin-2.23%
EBITDA Margin11.56%
Profit Margin0.22%
ROE0.25%
ROA0.14%
Growth
Revenue Growth-12.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF18.55M $
CapEx (TTM)1.81M $
FCF Margin13.21%
FCF Yield9.03%
Net Debt37.49M $
Net Debt/EBITDA3.56
Balance Sheet
Debt/Equity0.53
Current Ratio1.00
Quick Ratio0.87
Book Value/Sh17.27 PLN
Cash/Share1.084 PLN
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 PLN
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.5 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)36.35 PLN
Upside (mean)+26.2%
Target Range28.00 PLN – 47.10 PLN
PLN28.00+26.2% to meanPLN47.10
# Analysts6
Ownership
Shares Out.18.35M
Float9.71M
Insiders21.18%
Institutions27.27%
Technical
SMA 5029.17 (-1.3%)
SMA 20036.69 (-21.5%)
Beta0.08
S&P 52W Chg18.16%
Avg Vol (30d)26.52K
Avg Vol (10d)12.60K
Technical Indicators
RSI (14)53.8
MACD-0.1018
MACD Signal-0.3450
MACD Hist.+0.2432
BB Upper29.79 PLN
BB Middle27.37 PLN
BB Lower24.95 PLN
BB Width17.65%
ATR (14)0.9841 PLN
Vol Ratio (20d)0.35x